The hepatitis B virus X protein (HBx) is a critical virulence factor implicated in the development of hepatocellular carcinoma (HCC). Its ability to dysregulate host cell signaling pathways contributes significantly to uncontrolled proliferation, evasion of apoptosis, and cellular transformation. In this study, we focused on the role of HBx in modulating key intracellular signaling cascades—specifically the MEK/ERK and PI3K/Akt pathways—in hepatic oval cells, a population of liver progenitor cells involved in regeneration and tumorigenesis.
Using a stable LE/6 rat hepatic oval cell line engineered to express HBx, we first confirmed overexpression at the protein level via Western blotting. Functional analysis revealed that HBx-expressing cells exhibited significantly enhanced proliferation compared to control cells, as measured by MTT assay and direct cell counting. This proliferative effect was sustained over 72 hours and was most pronounced at 48 and 72 hours post-treatment, indicating a time-dependent increase in growth.
To understand the underlying molecular mechanisms, we investigated the activation status of major signaling kinases. Western blot analysis showed a marked increase in phosphorylated ERK1/2 (pERK) and phosphorylated Akt (pAkt) in HBx-transfected cells, while total ERK and Akt levels remained unchanged. This indicates selective activation of these pathways rather than general upregulation. In contrast, no significant changes were observed in pJNK or pp38, suggesting that JNK and p38 pathways are not involved in HBx-induced effects in this context.
We then employed specific pharmacological inhibitors to dissect pathway dependence. Treatment with PD184352, a MEK inhibitor, effectively blocked ERK phosphorylation and attenuated HBx-induced proliferation. Similarly, LY294002, a PI3K inhibitor, suppressed Akt activation and reduced cell growth. Notably, dual inhibition of both MEK and PI3K led to near-complete abrogation of proliferation, demonstrating that both pathways are essential for HBx-driven expansion of oval cells.
Further analysis confirmed that cyclin D1 expression, a downstream target of both ERK and Akt, was dramatically downregulated upon inhibitor treatment. qPCR results showed decreased cyclin D1 mRNA levels, while Western blotting revealed a parallel reduction in protein abundance. The suppression was more profound with LY294002 than PD184352, suggesting that PI3K/Akt signaling may play a dominant role in regulating cyclin D1 transcription or stability in these cells.
These findings establish that HBx promotes hepatic oval cell proliferation through coordinated activation of MEK/ERK and PI3K/Akt pathways.1,8-Dibromooctane Protocol The dependency on both cascades highlights their synergistic function in driving cell cycle progression. While the exact mechanism of cyclin D1 regulation remains partially unresolved, evidence points toward transcriptional activation via ERK-mediated phosphorylation of transcription factors such as Elk-1, and Akt-mediated inhibition of GSK-3β, which stabilizes cyclin D1 protein.2-Cyanophenothiazine Biological Activity
Importantly, despite strong inhibition by pharmacological agents, residual proliferation persisted, implying the existence of alternative or compensatory pathways.PMID:35084743 Potential candidates include NF-κB, STAT3, or Wnt/β-catenin signaling, all of which have been linked to HBx activity and can regulate cyclin D1 expression independently.
In conclusion, our data provide compelling evidence that HBx drives oval cell proliferation via activation of MEK/ERK and PI3K/Akt pathways, leading to upregulation of cyclin D1. These findings deepen our understanding of how HBV contributes to liver carcinogenesis through progenitor cell expansion and underscore the therapeutic potential of targeting these signaling axes in HBV-related HCC. Future studies should validate these mechanisms in primary human oval cells and in vivo models to translate these insights into clinical applications.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com